News
NTRA
319.82
+2.51%
7.84
Natera registers to sell 68,023 shares of common stock for holders
TipRanks · 3h ago
Arcutis Biotherapeutics And 2 Other Top Healthcare Stocks
Simply Wall St · 4h ago
Natera announces clinical collaboration with Incyte
TipRanks · 1d ago
ATFV, ZS, NTRA, TWLO: Large Outflows Detected at ETF
NASDAQ · 1d ago
Natera (NTRA) Moved, What Is Behind The Fresh Attention?
Simply Wall St · 1d ago
Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer
Benzinga · 2d ago
Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
NASDAQ · 2d ago
Natera price target lowered to $405 from $475 at Roth Capital
TipRanks · 3d ago
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha · 3d ago
Natera Price Target Cut to $403.00/Share From $458.00 by Baird
Dow Jones · 3d ago
Natera Is Maintained at Outperform by Baird
Dow Jones · 3d ago
Baird Maintains Outperform on Natera, Lowers Price Target to $403
Benzinga · 3d ago
Natera price target lowered to $403 from $458 at Baird
TipRanks · 3d ago
Weekly Report: what happened at NTRA last week (1102-1106)?
Weekly Report · 3d ago
Why Natera Stock Is Down 14.6% And What's Next
Simply Wall St · 4d ago
Natera Price Target Cut to $405.00/Share From $460.00 by JP Morgan
Dow Jones · 5d ago
Natera Is Maintained at Overweight by JP Morgan
Dow Jones · 5d ago
JP Morgan Maintains Overweight on Natera, Lowers Price Target to $405
Benzinga · 5d ago
Oversold Conditions For Natera (NTRA)
NASDAQ · 5d ago
Has Natera (NTRA) Left Enough Upside In Its Cash Flow Story?
Simply Wall St · 5d ago
More
Webull provides a variety of real-time NTRA stock news. You can receive the latest news about Natera Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.